A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.
DeFilipp Z, Kim HT, Cheng GS, Hamilton BK, Chhabra S, Hamadani M, Sandhu KS, Perez LE, Lee C, Brennan TL, Garrelts C, Brown BM, Gallagher KME, Newcomb RA, El-Jawahri A, Chen YB.
DeFilipp Z, et al. Among authors: perez le.
Blood Adv. 2024 Oct 4:bloodadvances.2024014000. doi: 10.1182/bloodadvances.2024014000. Online ahead of print.
Blood Adv. 2024.
PMID: 39365992